Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group.
Laupacis
A
A
Department of Medicine, University of Western Ontario, London, Canada.
D000203:Activities of Daily Living; D000328:Adult; D004311:Double-Blind Method; D004921:Erythropoietin / Q000627:therapeutic use*; D005221:Fatigue / Q000209:etiology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D014938:Work Capacity Evaluation
D011994:Recombinant Proteins; D004921:Erythropoietin